Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04146896 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)
A Phase 2 study, sponsored by Aptinyx.
- Completed
- Registry status
- Phase 2
- Development phase
- 228
- Enrollment target
NCT04146896 is a Phase 2 study that has completed, run by Aptinyx. The registered enrollment target is 228 participants.
The verdict
NCT04146896, a Phase 2 study, has completed, sponsored by Aptinyx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 228 participants
- Enrollment target
Study Summary
To evaluate the efficacy of NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy.
Interventions
- DRUG Placebo
- DRUG NYX-2925 50 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 228 participants |
| Start Date | 2019-11-12 |
| Est. Completion | 2022-02-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04146896
The ClinicalTrials.gov registry entry for NCT04146896 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 228 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Aptinyx, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04146896 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04146896 about?
NCT04146896 is a clinical study titled "Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy (DPN)". To evaluate the efficacy of NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy.
What is the current status of trial NCT04146896?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 228 participants. The study started on 2019-11-12. Estimated completion is 2022-02-23.
What interventions are being tested in trial NCT04146896?
The interventions under investigation include: Placebo (DRUG), NYX-2925 50 mg (DRUG).
Who is sponsoring clinical trial NCT04146896?
This trial is sponsored by Aptinyx, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.